Last reviewed · How we verify

NCT05431738: ANTIMIG

Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)

Recruiting now NA Last updated 30 July 2024
What this trial tests

NA trial testing Gastroesophageal stent placement in Stent Migration in 180 participants. Currently enrolling.

Timeline
1 September 2022
Primary endpoint
1 September 2025
1 September 2025

Quick facts

Lead sponsorSociété Française d'Endoscopie Digestive
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment180
Start date1 September 2022
Primary completion1 September 2025
Estimated completion1 September 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Société Française d'Endoscopie Digestive — full company profile →

Who can join

Adults 18 to 91, any sex, with Stent Migration or GastroEsophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this prospective, controlled, randomized, multicentre, single-blind study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally advanced or metastatic malignant stenosis of the gastroesophageal junction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stent Migration

Currently open trials in the same condition.

Other Société Française d'Endoscopie Digestive trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05431738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing